Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
about
Half-life of IgE in serum and skin: Consequences for anti-IgE therapy in patients with allergic disease.A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy.IgE, mast cells, basophils, and eosinophils.Polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) gene are associated with susceptibility to asthma.Long-term benefits of omalizumab in a patient with severe non-allergic asthmaBasophil CD203c levels are increased at baseline and can be used to monitor omalizumab treatment in subjects with nut allergyEvidence that FcRn mediates the transplacental passage of maternal IgE in the form of IgG anti-IgE/IgE immune complexes.A review of anti-IgE monoclonal antibody (omalizumab) as add on therapy for severe allergic (IgE-mediated) asthmaAnti-IgE treatment of eosinophil-associated gastrointestinal disorders.Omalizumab for pediatric asthma.Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies.Therapeutic monoclonal antibody concentration monitoring: free or total?Biotherapeutic bioanalysis: a multi-indication case study review.Omalizumab for treatment of allergic rhinitis.Impact of Shed/Soluble targets on the PK/PD of approved therapeutic monoclonal antibodies.Structure of the omalizumab Fab.A long term case series study of the effect of omalizumab on chronic spontaneous urticaria.A simple method for measuring human cell-bound IgE levels in whole blood.Immuno-evasive tactics by schistosomes identify an effective allergy preventative.Immunologic effects of omalizumab in children with severe refractory atopic dermatitis: a randomized, placebo-controlled clinical trial.Rhinovirus and serum IgE are associated with acute asthma exacerbation severity in childrenMeasured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab.A humanized mouse model of anaphylactic peanut allergy.Omalizumab Is Associated with Reduced Acute Severity of Rhinovirus-triggered Asthma Exacerbation.The recovery-ELISA--a novel assay technique to monitor therapy with humanized antibodies: the example of omalizumab.Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction.Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.Reduction of the total IgE level by omalizumab in children and adolescents.Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma.Variability of total and free IgE levels and IgE receptor expression in allergic subjects in and out of pollen season.Regulation of IgE activity in inhalational tolerance via formation of IgG anti-IgE/IgE immune complexes.Effect of omalizumab on biomarkers in middle ear effusion in patients with eosinophilic otitis media
P2860
Q30276181-B5A1C80D-719A-4FC4-B057-AC685CB1B3D1Q33574876-E230BF46-E17A-471B-A8C9-5C9857508F27Q33760398-37307F86-DCAF-4C06-A4D3-708E0996E56BQ34329191-06EBC050-B2D3-4EF7-82D3-25B80223CF6DQ35078215-4BD84B54-16B5-4697-A090-3F5CA7F5FA23Q35546493-945CB1A3-0B97-4410-BEEF-BA16FB3E02DBQ35624937-4BDD8EED-89BC-4941-8758-3C92395246D8Q36642971-3F57EFC1-B46B-4C80-B2B8-B8C2410E07D1Q37401252-66BD0106-27BC-44CF-A885-E0FDD4550526Q37800937-051BC6D9-2DD0-450B-A67A-57A6041897BFQ37810155-70A1F45B-38A9-4FFF-95B7-5A8A3276CBEBQ37810218-F441D0B6-9848-4387-993A-9A01F66DC9F1Q37854629-1F058C64-258D-4800-939D-93AA9334F37AQ38101972-8C846376-3D15-48FD-BC81-9CCA6BBEBA80Q38987211-5817309B-220B-45CC-A77D-AFBE570E7773Q39335284-3A9ED6D1-09A3-4DCF-B029-BB6266825AF9Q40993100-FCA25857-4DFB-4597-8874-A1635786FE40Q41213396-8D653073-B6AB-492F-9C6E-7621F0C0F69DQ41373939-635221C3-D774-49BF-B6FF-EA5036D62B39Q42139482-9C74DC3B-DB9C-4B0C-A69D-24739936D64CQ42736158-7CC79667-EA33-48D1-9DBA-5B3567DEFC81Q44924204-EEAF5D69-2032-46B7-93EC-D9A130E7C149Q45038124-15BB4B8C-2BEE-4DF0-B667-34B405C3F0B9Q45898148-DFECF643-2FBF-4A28-B3C5-7EC905FE681AQ45948227-24B6F518-DA23-4379-82C9-52E6D2D1767BQ47203998-F1176813-D951-4CA2-AFA6-2294386B559BQ48484600-01C6AD75-45C7-4DDD-BFC6-8F28E25D4ACFQ52690504-8EAC2E10-A8F3-4313-98F8-03E0DED9EEABQ52931077-A274CFCA-738A-4B99-9942-A749E0E7C57FQ53628624-BFF45142-B69C-4C91-B3AF-9A15EAC9D4CDQ55052500-0FCACBAB-8D7F-45AC-A748-3FC14A37F18DQ58299909-A95687A4-8951-4DAF-98CC-9F7A3360B189
P2860
Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Immunological methods for quan ...... g omalizumab (Xolair) therapy.
@en
Immunological methods for quan ...... patients receiving omalizumab
@nl
type
label
Immunological methods for quan ...... g omalizumab (Xolair) therapy.
@en
Immunological methods for quan ...... patients receiving omalizumab
@nl
prefLabel
Immunological methods for quan ...... g omalizumab (Xolair) therapy.
@en
Immunological methods for quan ...... patients receiving omalizumab
@nl
P2093
P1476
Immunological methods for quan ...... g omalizumab (Xolair) therapy.
@en
P2093
Gregory V Marcotte
Robert G Hamilton
Sarbjit S Saini
P356
10.1016/J.JIM.2005.06.008
P577
2005-08-01T00:00:00Z